Systematic review: Prevention of travellers' diarrhoea

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 9, 2008, Pages 741-751

  DuPont, H L ^a,b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BICOZAMYCIN; BISMUTH SALICYLATE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CIPROFLOXACIN; CLIOQUINOL; COTRIMOXAZOLE; DOXYCYCLINE; ESCHERICHIA COLI VACCINE; LEVOFLOXACIN; NEOMYCIN; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SULFONAMIDE;

ABSENCE OF SIDE EFFECTS; AFRICA; ANTIBIOTIC PROPHYLAXIS; BEVERAGE; BRAIN DISEASE; CHEMOPROPHYLAXIS; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES COLOR; FOOD; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MEDLINE; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOUTH AMERICA; SOUTH ASIA; SYSTEMATIC REVIEW; TINNITUS; TONGUE DISCOLORATION; TRAVEL; TRAVELLER DIARRHEA; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; ANTI-BACTERIAL AGENTS; DIARRHEA; DIET; FOOD MICROBIOLOGY; HUMANS; HYGIENE; RISK FACTORS; TRAVEL; WATER MICROBIOLOGY;

EID: 41749090688     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03647.x     Document Type: Review

References (97)

1. DuPont HL, Haynes GA, Pickering LK, et al. Diarrhea of travelers to Mexico. Relative susceptibility of United States and Latin American students attending a Mexican University. Am J Epidemiol 1977 105 : 37 41.
2. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005 142 : 805 12.
3. Kean BH. The diarrhea of travelers to Mexico. Summary of five-year study. Ann Intern Med 1963 59 : 605 14.
4. Black RE. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990 12 (Suppl. 1 S73 9.
5. Gorbach SL, Kean BH, Evans DG, et al. Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med 1975 292 : 933 6.
6. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002 185 : 497 502.
7. Kean BH, Schaffner W, Brennan RW. The diarrhea of travelers: V. Prophylaxis with phthalylsulfathiazole and neomycin sulphate. JAMA 1962 180 : 367 71.
8. Kean BH, Waters S. The diarrhea of travelers: I. Incidence in travelers returning to the United States from Mexico. AMA Arch Ind Health 1958 18 : 148 50.
9. Gorbach S, Edelman R. Travelers' diarrhea: National Institutes of Health Consensus Development Conference. Rev Infect Dis 1986 8 (Suppl. 2 S109 233.
10. Pimentel M, Riddle MS. Prevention of traveler's diarrhea: a call to reconvene. Clin Infect Dis 2008 46 : 151 2.
11. Jiang ZD, Mathewson JJ, Ericsson CD, et al. Characterization of enterotoxigenic Escherichia coli strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992-1997. J Infect Dis 2000 181 : 779 82.
12. Brown MR, DuPont HL, Sullivan PS. Effect of duration of exposure on diarrhea due to enterotoxigenic Escherichia coli in travelers from the United States to Mexico. J Infect Dis 1982 145 : 582.
13. DuPont HL, Olarte J, Evans DG, et al. Comparative susceptibility of Latin American and united states students to enteric pathogens. N Engl J Med 1976 295 : 1520 1.
14. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993 328 : 1821 7.
15. Steffen R, Tornieporth N, Clemens SA, et al. Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med 2004 11 : 231 7.
16. von Sonnenburg F, Tornieporth N, Waiyaki P, et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000 356 : 133 4.
17. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004 99 : 1774 8.
18. Stermer E, Lubezky A, Potasman I, et al. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006 43 : 898 901.
19. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003 98 : 1578 83.
20. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003 124 : 1662 71.
21. Thornley JP, Jenkins D, Neal K, et al. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001 184 : 606 9.
22. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002 51 : 410 3.
23. Yates JA, Stetz LC. Reiter's syndrome (reactive arthritis) and travelers' diarrhea. J Travel Med 2006 13 : 54 6.
24. Adachi JA, Mathewson JJ, Jiang ZD, et al. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med 2002 136 : 884 7.
25. Merson MH, Morris GK, Sack DA, et al. Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress. N Engl J Med 1976 294 : 1299 305.
26. Tjoa WS, DuPont HL, Sullivan P, et al. Location of food consumption and travelers' diarrhea. Am J Epidemiol 1977 106 : 61 6.
27. Wood LV, Ferguson LE, Hogan P, et al. Incidence of bacterial enteropathogens in foods from Mexico. Appl Environ Microbiol 1983 46 : 328 32.
28. Kozicki M, Steffen R, Schar M. 'Boil it, cook it, peel it or forget it': does this rule prevent travellers' diarrhoea? Int J Epidemiol 1985 14 : 169 72.
29. Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin Infect Dis 2005 41 (Suppl. 8 S531 5.
30. Owen JR. Diarrhoea at the Olympics. Br Med J 1968 4 : 645.
31. Sack DA, Kaminsky DC, Sack RB, et al. Prophylactic doxycycline for travelers' diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med 1978 298 : 758 63.
32. Sack RB, Froehlich JL, Zulich AW, et al. Prophylactic doxycycline for travelers' diarrhea: results of a prospective double-blind study of Peace Corps volunteers in Morocco. Gastroenterology 1979 76 : 1368 73.
33. DuPont HL, Evans DG, Rios N, et al. Prevention of travelers' diarrhea with trimethoprim-sulfamethoxazole. Rev Infect Dis 1982 4 : 533 9.
34. DuPont HL, Galindo E, Evans DG, et al. Prevention of travelers' diarrhea with trimethoprim-sulfamethoxazole and trimethoprim alone. Gastroenterology 1983 84 : 75 80.
35. Sack RB, Santosham M, Froehlich JL, et al. Doxycycline prophylaxis of travelers' diarrhea in Honduras, an area where resistance to doxycycline is common among enterotoxigenic Escherichia coli. Am J Trop Med Hyg 1984 33 : 460 6.
36. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001 45 : 212 6.
37. Ericsson CD, Evans DG, DuPont HL, et al. Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae. J Infect Dis 1977 136 : 693 6.
38. DuPont HL, Sullivan P, Pickering LK, et al. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 1977 73 : 715 8.
39. DuPont HL, Sullivan P, Evans DG, et al. Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA 1980 243 : 237 41.
40. DuPont HL, Ericsson CD, Johnson PC, et al. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 1987 257 : 1347 50.
41. Powell DW, Tapper EJ, Morris SM. Aspirin-stimulated intestinal electrolyte transport in rabbit ileum in vitro. Gastroenterology 1979 76 : 1429 37.
42. Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology 1983 85 : 1017 22.
43. Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob Agents Chemother 1986 30 : 671 4.
44. Rademaker CM, Hoepelman IM, Wolfhagen MJ, et al. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis 1989 8 : 690 4.
45. Scott DA, Haberberger RL, Thornton SA, Hyams KC. Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am J Trop Med Hyg 1990 42 : 160 4.
46. Wistrom J, Norrby SR, Burman LG, et al. Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. J Antimicrob Chemother 1987 20 : 563 74.
47. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005 353 : 2433 41.
48. Ericsson CD, DuPont HL, Galindo E, et al. Efficacy of bicozamycin in preventing traveler's diarrhea. Gastroenterology 1985 88 : 473 7.
49. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 33 : 1807 15.
50. DuPont H, Ericsson C, Jiang Z-D, et al. Prevention of Travelers' Diarrhea with Rifaximin - A Phase 3 Randomized Double-blind Placebo-controlled Trial in U.S. Students in Mexico. 71st Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, 2006 Abstract 516.
51. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000 44 : 2205 6.
52. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 10 : 1009 11.
53. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006 42 : 1283 8.
54. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007 44 : 338 46.
55. DuPont HL. Azithromycin for the self-treatment of traveler's diarrhea. Clin Infect Dis 2007 44 : 347 9.
56. Hilton E, Kolakowski P, Singer C, Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 1997 4 : 41 3.
57. Briand V, Buffet P, Genty S, et al. Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis 2006 43 : 1170 5.
58. de dios Pozo-Olano J, Warram JH Jr., Gomez RG, Cavazos MG. Effect of a lactobacilli preparation on traveler's diarrhea. A randomized, double blind clinical trial. Gastroenterology 1978 74 : 829 30.
59. Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med 1993 111 : 152 6.
60. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007 41 : 1859 66.
61. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005 41 : 118 21.
62. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005 40 : 1625 34.
63. Clemens JD, Harris JR, Sack DA, et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis 1988 158 : 60 9.
64. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991 338 : 1285 9.
65. Clemens J, Savarino S, Abu-Elyazeed R, et al. Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. J Infect Dis 2004 189 : 2299 307.
66. Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 1998 16 : 255 60.
67. Sack DA, Shimko J, Torres O, et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 2007 25 : 4392 400.
68. Guerena-Burgueno F, Hall ER, Taylor DN, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002 70 : 1874 80.
69. Yu J, Cassels F, Scharton-Kersten T, et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 2002 70 : 1056 68.
70. Glenn GM, Villar CP, Flyer DC, et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007 75 : 2163 70.
71. McKenzie R, Bourgeois AL, Frech SA, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007 25 : 3684 91.
72. Frech SA, DuPont HL, Bourgeois AL, et al. Protection against travelers' diarrhea in a randomized, double-blind, placebo-controlled field trial of a patch containing heat-labile toxin from Escherichia coli. Lancet 2008 (in press).
73. Allen KP, Randolph MM, Fleckenstein JM. Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains. Infect Immun 2006 74 : 869 75.
74. Farthing MJG, DuPont HL, Guandalini S, et al. Treatment and prevention of travellers' diarrhoea. Gastroenterol Int 1992 5 : 162 75.
75. Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005 142 : 861 2.
76. Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006 43 : 1185 93.
77. Jiang ZD, Okhuysen PC, Guo DC, et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003 188 : 506 11.
78. Mohamed JA, DuPont HL, Jiang ZD, et al. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis 2007 44 : 945 52.
79. Nalin DR, Levine RJ, Levine MM, et al. Cholera, non-vibrio cholera, and stomach acid. Lancet 1978 2 : 856 9.
80. Sack GH Jr., Pierce NF, Hennessey KN, et al. Gastric acidity in cholera and noncholera diarrhoea. Bull World Health Organ 1972 47 : 31 6.
81. Van Loon FP, Clemens JD, Shahrier M, et al. Low gastric acid as a risk factor for cholera transmission: application of a new non-invasive gastric acid field test. J Clin Epidemiol 1990 43 : 1361 7.
82. Tuteja AK, Talley NJ, Gelman SS, et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci 2008 53 : 271 6.
83. Levine MM, Hornick RB. Lactulose therapy in Shigella carrier state and acute dysentery. Antimicrob Agents Chemother 1975 8 : 581 4.
84. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003 37 : 1165 71.
85. Kassenborg HD, Smith KE, Vugia DJ, et al. Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis 2004 38 (Suppl. 3 S279 84.
86. Bandres JC, Mathewson JJ, DuPont HL. Heat susceptibility of bacterial enteropathogens. Implications for the prevention of travelers' diarrhea. Arch Intern Med 1988 148 : 2261 3.
87. Lynch M, Painter J, Woodruff R, Braden C. Surveillance for foodborne-disease outbreaks - United States, 1998-2002. MMWR Surveill Summ 2006 55 : 1 42.
88. Kean BH, Waters SR. The diarrhea of travelers: III. Drug prophylaxis in Mexico. N Engl J Med 1959 261 : 71 4.
89. Richards DA. Prophylactic value of clioquinol against travellers' diarrhoea. Lancet 1971 1 : 44 5.
90. Schultz MG. Entero-Vioform for preventing travelers' diarrhea. JAMA 1972 220 : 273 4.
91. Gordon MF, Abrams RI, Rubin DB, et al. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. Mov Disord 1995 10 : 220 2.
92. Hasking GJ, Duggan JM. Encephalopathy from bismuth subsalicylate. Med J Aust 1982 2 : 167.
93. Jungreis AC, Schaumburg HH. Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol). Neurology 1993 43 : 1265.
94. Mendelowitz PC, Hoffman RS, Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med 1990 112 : 140 1.
95. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988 158 : 372 7.
96. Scerpella EG, Sanchez JL, Mathewson IJ, et al. Safety, immunogenicity, and protective efficacy of the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J Travel Med 1995 2 : 22 7.
97. Hall ER, Wierzba TF, Ahren C, et al. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Infect Immun 2001 69 : 2853 7.